Key Highlights
- Hemab Therapeutics reported Phase 2 long-term extension data for sutacimig (HMB-001) in Glanzmann thrombasthenia, showing a 92% reduction in treated bleeding events across 34 patients with up to 15.9 months of drug exposure.
- The low-dose cohort showed an 84% reduction in the mean annualized treated bleeding rate (ATBR), alongside successful hemostatic control across three surgical procedures.
- The trial confirmed a tolerable safety profile, with Grade 2 thromboembolic events limited to high-exposure or multi-risk-factor patient groups.
- Following positive preclinical data in Factor VII deficiency and FDA alignment on a 0.2mg/kg weekly dose, Hemab plans to initiate a registration-directed Phase 3 trial during the second half of 2026.
Hemab Therapeutics (NASDAQ: COAG) reported favorable clinical outcomes from its Phase 2 long-term extension study of sutacimig (HMB-001), evaluated for the subcutaneous prevention of bleeding events in patients with Glanzmann thrombasthenia (GT), a rare inherited platelet disorder that impairs normal blood clot formation and can lead to significant and sometimes life-threatening bleeding episodes.
The long-term extension data, drawn from 34 patients with up to 15.9 months of drug exposure, showed a 92% reduction in treated bleeding events, a substantial improvement that speaks to sutacimig's potential to meaningfully reduce the bleeding burden faced by patients with this rare and difficult-to-manage condition. In the low-dose cohort specifically, the study showed an 84% reduction in the mean annualized treated bleeding rate (ATBR), a standardized measure that normalizes bleeding frequency over a full year, allowing for more direct comparison across patients and treatment periods.
Beyond routine bleeding prevention, the trial also confirmed successful hemostatic control across three surgical procedures performed on patients receiving sutacimig. Surgical settings represent a particularly high-risk scenario for patients with bleeding disorders like Glanzmann thrombasthenia, so demonstrating effective clot formation and bleeding control during these procedures provides important supportive evidence for the drug's clinical utility beyond everyday bleeding prophylaxis.
Safety data from the extension study showed a tolerable profile overall, with Grade 2 thromboembolic events limited specifically to high-exposure or multi-risk-factor patient groups. This finding is clinically important, as it suggests the thromboembolic risk associated with sutacimig — a relevant safety consideration for any therapy designed to enhance clotting in patients with a bleeding disorder — appears to be concentrated in identifiable higher-risk subgroups rather than occurring broadly across the treated population, information that could help guide patient selection and dosing strategies in future development.
Hemab also disclosed positive preclinical data in Factor VII deficiency, a separate rare bleeding disorder, suggesting the company sees potential for sutacimig's mechanism to extend beyond Glanzmann thrombasthenia into additional rare bleeding disorder indications. The company further noted alignment with the FDA on a 0.2mg/kg weekly dose, an important regulatory milestone that provides clarity on the specific dosing regimen expected to move forward into pivotal-stage development.
Building on this combination of long-term extension efficacy and safety data, positive preclinical signals in a second indication, and FDA dose alignment, Hemab plans to initiate its registration-directed Phase 3 trial for sutacimig in Glanzmann thrombasthenia during the second half of 2026, representing the next major milestone in the drug's path toward a potential approval for this rare disease population.






Please wait processing your request...